Chikungunya vaccine candidate causes successful development of antibodies against the virus

Chikungunya Vaccine Candidate Passes Phase I Clinical Trials

Chikungunya vaccine candidate causes successful development of antibodies against the virus Chikungunya, a mosquito borne virus, has recently been responsible for outbreaks in the Caribbean and the Pacific. Although the disease is not usually fatal, it causes similar symptoms to a bad flu: muscle aches, malaise and headaches. However, one of the unique aspects of the virus is that it …

Ebola Virus Gene Replikin Count Increased Sixteen-fold in 2013 in Advance of Current Outbreaks

July 30th, 2014 Replikins Ltd. today released new data on changes in the gene structure of the Ebola virus. Before the current outbreaks, the mean Ebola Reston gene Replikin Count (number of Replikins per 100 amino acids) between 1995 and 2002 was 1.1; the mean Replikin Count increased twofold in 2010, threefold in 2012, and sixteen-fold in 2013, thus predicting …

Respiratory syncytial virus (RSV): Potential significant opportunity for effective vaccine

  Pioneering new research into respiratory syncytial virus (RSV) may have overcome the barriers that have impeded the development of an effective vaccine against the deadly virus. RSV is a virus that causes lower respiratory tract infections and is a major cause of childhood morbidity and mortality worldwide. Attempts to develop vaccines against the virus in the 1960s were dogged …

Dr Joseph Fair from Global Viral Forecasting Institute discussed today #wvcusa: Preventing epidemics – the virus hunt continues

Today at the World Vaccine Congress, Dr Joseph Fair delivered a presentation on preventing epidemics. Dr. Fair’s group is dedicated to identifying emerging pandemics before they happen.  Dr. Fair says that we know that in Brazzaville Congo, in 1929, there were at least a few people walking around with HIV/AIDS.  If we knew then, what could we have done to …